Phase 1a/1b clinical study of APP-111 in treatment of form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists and testosterone reducing agents

Trial Profile

Phase 1a/1b clinical study of APP-111 in treatment of form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists and testosterone reducing agents

Planning
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs APP 111 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Oct 2015 New trial record
    • 01 Oct 2015 According to an Aspen Park Pharmaceutical media release, this trial is expected to begin in late 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top